All‐cause mortality rate at 30 days · adults having abdominal surgery
Epidural analgesia showed no clear difference in all‐cause mortality rate at 30 days compared with intravenous patient‐controlled analgesia (low certainty).
1 finding from 1 review
Intervention not reported
Overall mortality (30‐day postoperative; procedure‐ and non‐procedure related) · patients with stones in the gallbladder and common bile duct undergoing laparoscopic cholecystectomy
1 finding from 1 review
Intervention not reported
Overall morbidity (30‐day postoperative; procedure‐ and non‐procedure related) · patients with stones in the gallbladder and common bile duct undergoing laparoscopic cholecystectomy
The intervention showed no clear difference in overall morbidity (30‐day postoperative; procedure‐ and… (low certainty).
1 finding from 1 review
All‐cause mortality Up to 28 days following admission · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 28 days following admission compared with inactive Control (moderate certainty).
1 finding from 1 review
Arterial thrombotic events ‐ up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Prophylactic trials: intervention showed no clear difference in arterial thrombotic events Up to 30 days post‐operatively compared with inactive control (low certainty).
2 findings from 1 review
Venous thrombotic events Up to 4 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thromboembolic events Post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in arterial thromboembolic events Up to 30 days post‐operatively compared with inactive control (low certainty).
1 finding from 1 review
All‐cause mortality In‐hospital mortality up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality In‐hospital mortality up to 30 days… compared with inactive Control (low certainty).
1 finding from 1 review
Venous thromboembolic events Up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in venous thromboembolic events Up to 30 days post‐operatively compared with inactive control (low certainty).
1 finding from 1 review
All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 46 days post‐operatively compared with inactive Control (high certainty).
1 finding from 1 review
All‐cause mortality Up to 7 days post‐operatively or hospital discharge · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
2 findings from 1 review
Venous thromboembolic events Up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thrombotic events Up to 4 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Intervention not reported
Next‐day alertness Participant reports. Scale from: 0 to 10 points; higher scores equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review
Quality of sleep · adults with insomnia
1 finding from 1 review
Mortality: in‐hospital mortality (within 7 days) · all conditions
It is very uncertain whether transfusion of RBCs of shorter changes mortality: in‐hospital mortality (within 7 days) compared with longer storage duration (very low certainty).
1 finding from 1 review
Mortality: short term (up to 30 days) · all conditions
Transfusion of RBCs of shorter showed no clear difference in mortality: short term (up to 30 days) compared with longer storage duration (low certainty).
1 finding from 1 review
Mortality: short‐term mortality (up to 30 days) ‐ neonates · all conditions
It is very uncertain whether transfusion of RBCs of shorter changes mortality: short‐term mortality (up to 30 days) ‐ neonates compared with standard practice storage duration (very low certainty).
1 finding from 1 review
Mortality: short‐term mortality (up to 30 days) ‐ adults · all conditions
Transfusion of RBCs of shorter showed no clear difference in mortality: short‐term mortality (up to 30 days) ‐ adults compared with standard practice storage duration (moderate certainty).
1 finding from 1 review